Alan Colowick

967 total citations
19 papers, 798 citations indexed

About

Alan Colowick is a scholar working on Hematology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Alan Colowick has authored 19 papers receiving a total of 798 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 4 papers in Pediatrics, Perinatology and Child Health and 4 papers in Oncology. Recurrent topics in Alan Colowick's work include Erythropoietin and Anemia Treatment (12 papers), Iron Metabolism and Disorders (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Alan Colowick is often cited by papers focused on Erythropoietin and Anemia Treatment (12 papers), Iron Metabolism and Disorders (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Alan Colowick collaborates with scholars based in United States, Austria and Canada. Alan Colowick's co-authors include John A. Glaspy, Giuseppe Rossi, Glen R. Justice, Jerry Avorn, Rhonda L. Bohn, Bruce M. Ewenstein, N. Simon Tchekmedyian, Lee S. Schwartzberg, Gregory Rossi and J. Keßler and has published in prestigious journals such as Blood, Cancer and The Journal of Urology.

In The Last Decade

Alan Colowick

19 papers receiving 747 citations

Peers

Alan Colowick
Clemens Leitgeb Austria
Magnus Adriansson Sweden
Frank C. Dougherty Switzerland
José Chang Canada
Irene Ferreira Spain
S. Luzi Fedeli Italy
T. Littlewood United Kingdom
M. Puntous France
G. P. Summerfield United Kingdom
Monique Steijaert Netherlands
Clemens Leitgeb Austria
Alan Colowick
Citations per year, relative to Alan Colowick Alan Colowick (= 1×) peers Clemens Leitgeb

Countries citing papers authored by Alan Colowick

Since Specialization
Citations

This map shows the geographic impact of Alan Colowick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Colowick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Colowick more than expected).

Fields of papers citing papers by Alan Colowick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Colowick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Colowick. The network helps show where Alan Colowick may publish in the future.

Co-authorship network of co-authors of Alan Colowick

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Colowick. A scholar is included among the top collaborators of Alan Colowick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Colowick. Alan Colowick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Chiorean, E. Gabriela, Tomislav Dragovich, John Hamm, et al.. (2007). A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology. 61(6). 1019–1026. 12 indexed citations
2.
Chiorean, Elena G., Tomislav Dragovich, John Hamm, et al.. (2007). 3523 POSTER Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: results of a Phase 2 trial. European Journal of Cancer Supplements. 5(4). 266–266. 1 indexed citations
3.
Ammons, W. S., et al.. (2006). 1453: Lonidamine Reduces Prostate Weight in Rodents and is Accompanied by Apoptosis and Disruption of the Epithelial Cell Layer. The Journal of Urology. 175(4S). 469–469. 1 indexed citations
4.
5.
Kotasek, Dusan, G. Steger, Wylam Faught, et al.. (2003). Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. European Journal of Cancer. 39(14). 2026–2034. 119 indexed citations
6.
7.
Smith, Robert E., N. Simon Tchekmedyian, Luís Meza, et al.. (2003). A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. British Journal of Cancer. 88(12). 1851–1858. 62 indexed citations
8.
Langer, Corey J., Hak Choy, John A. Glaspy, & Alan Colowick. (2002). Standards of care for anemia management in oncology. Cancer. 95(3). 613–623. 26 indexed citations
9.
Glaspy, John A., Glen R. Justice, J. Keßler, et al.. (2002). Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer. 87(3). 268–276. 138 indexed citations
10.
Mirtsching, B., Veena Charu, Saroj Vadhan‐Raj, et al.. (2002). Every-2-Week Darbepoetin Alfa Is Comparable to rHuEPO in Treating Chemotherapy-Induced Anemia. 10 indexed citations
11.
Mirtsching, B., Veena Charu, Saroj Vadhan‐Raj, et al.. (2002). Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.. PubMed. 16(10 Suppl 11). 31–6. 16 indexed citations
12.
Smith, Robert E., Ishmael Jaiyesimi, Luís Meza, et al.. (2001). Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. British Journal of Cancer. 84(s1). 24–30. 69 indexed citations
13.
Glaspy, John A., Glen R. Justice, J. Keßler, et al.. (2001). A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. British Journal of Cancer. 84(s1). 17–23. 62 indexed citations
14.
15.
Smith, Ross C., Simon Tchekmedyian, Tak Mao Chan, et al.. (2001). Open-label, phase dose escalation study of NESP in patients with chronic anemia of cancer. European Journal of Cancer. 37. S355–S355. 11 indexed citations
16.
Glaspy, John A., Glen R. Justice, J. Keßler, et al.. (2001). Randomized, active-controlled, phase , dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors. European Journal of Cancer. 37. S353–S353. 17 indexed citations
17.
Hedenus, Michael, et al.. (2000). A randomized, blinded, placebo-controlled, phase II, dose-finding study of ARANESP (TM) in patients with lymphoproliferative malignancies.. Blood. 96(11). 15516. 4 indexed citations
18.
Colowick, Alan, Rhonda L. Bohn, Jerry Avorn, & Bruce M. Ewenstein. (2000). Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood. 96(5). 1698–1702. 84 indexed citations
19.
Colowick, Alan, Rhonda L. Bohn, Jerry Avorn, & Bruce M. Ewenstein. (2000). Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood. 96(5). 1698–1702. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Clemens Leitgeb Breakdown of academic impact, for papers by Magnus Adriansson Breakdown of academic impact, for papers by Frank C. Dougherty Breakdown of academic impact, for papers by José Chang Breakdown of academic impact, for papers by Irene Ferreira Breakdown of academic impact, for papers by S. Luzi Fedeli Breakdown of academic impact, for papers by T. Littlewood Breakdown of academic impact, for papers by M. Puntous Breakdown of academic impact, for papers by G. P. Summerfield Breakdown of academic impact, for papers by Monique Steijaert
Rankless by CCL
2026